Cagrilintide is an investigational long-acting amylin analog studied for its potential role in weight management and metabolic health. Research suggests it may promote satiety, reduce food intake, and improve glucose control when studied alone or in combination with other incretin-based therapies. Because of its extended half-life, Cagrilintide has become a compound of interest in obesity and diabetes-related studies.
Black Pearl Labs sells products intended for research and laboratory use only.
Products are not for human or animal consumption and are not approved for diagnostic, therapeutic, or clinical use.
By entering this website, you confirm that: